A 28-year-old female patient with a family history of prolonged apnea after general anesthesia is scheduled for elective surgery. She has never undergone anesthesia before. Which investigation is most appropriate to assess her risk of prolonged neuromuscular blockade with succinylcholine?

Explanation

## Clinical Context The patient has a **family history of prolonged apnea** after general anesthesia, which is the classic presentation of **pseudocholinesterase (butyrylcholinesterase) deficiency**. This is a pharmacogenetic disorder affecting the metabolism of succinylcholine and mivacurium. ## Investigation of Choice **Key Point:** The investigation of choice is **serum pseudocholinesterase (butyrylcholinesterase) activity assay combined with genetic phenotyping** to confirm the diagnosis and determine the specific variant. ### Why This Investigation? 1. **Direct Assessment of Drug Metabolism** - Pseudocholinesterase is the enzyme responsible for hydrolysis of succinylcholine - Low activity or abnormal variants lead to prolonged blockade (apnea) - Directly measures the defect responsible for the clinical problem 2. **Genetic Phenotyping** - Identifies the specific variant: normal (E~u~E~u~), heterozygous (E~u~E~a~), or homozygous atypical (E~a~E~a~) - Homozygous atypical: blockade lasts 4–8 hours instead of 5–10 minutes - Heterozygous: blockade lasts 20–30 minutes - Guides anesthetic management and family screening 3. **Preoperative Risk Stratification** - Allows avoidance of succinylcholine and mivacurium - Enables patient and family counseling - Prevents perioperative complications (prolonged apnea, need for mechanical ventilation) ## Comparison of Investigations | Investigation | Purpose | Utility in This Case | |---|---|---| | **Pseudocholinesterase activity + phenotyping** | Measures enzyme activity and genetic variant | **Gold standard**; directly assesses risk; guides drug avoidance | | **Train-of-four test** | Monitors neuromuscular blockade intraoperatively | Useful during anesthesia, not for preoperative diagnosis | | **Muscle biopsy with CHCT** | Diagnoses malignant hyperthermia | Not relevant; family history suggests pseudocholinesterase deficiency, not MH | | **EMG** | Assesses neuromuscular transmission | Baseline EMG is normal in pseudocholinesterase deficiency | ## High-Yield Facts **High-Yield:** Prolonged apnea after succinylcholine or mivacurium is pathognomonic for pseudocholinesterase deficiency. The diagnosis is confirmed by **serum pseudocholinesterase activity assay and genetic phenotyping**, not by intraoperative monitoring or muscle biopsy. **Mnemonic: PChE** — **P**seudocholinesterase **Ch**olinesterase **E**nzyme deficiency → Prolonged blockade with succinylcholine. **Clinical Pearl:** Patients with pseudocholinesterase deficiency should wear a medical alert bracelet and carry a card stating their diagnosis. Relatives should be screened preoperatively. **Warning:** Do not confuse pseudocholinesterase deficiency (pharmacogenetic) with malignant hyperthermia (pharmacogenetic but different mechanism). MH presents with muscle rigidity and hyperthermia; pseudocholinesterase deficiency presents with prolonged apnea only. [cite:Miller's Anesthesia 8e Ch 10]